1. Home
  2. GGR vs TIL Comparison

GGR vs TIL Comparison

Compare GGR & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gogoro Inc.

GGR

Gogoro Inc.

HOLD

Current Price

$3.61

Market Cap

88.6M

ML Signal

HOLD

Logo Instil Bio Inc.

TIL

Instil Bio Inc.

HOLD

Current Price

$11.04

Market Cap

177.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GGR
TIL
Founded
2011
2018
Country
Taiwan
United States
Employees
N/A
N/A
Industry
Auto Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
88.6M
177.1M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
GGR
TIL
Price
$3.61
$11.04
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$100.67
AVG Volume (30 Days)
15.6K
72.7K
Earning Date
11-11-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$280,211,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$6.15
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.55
$10.70
52 Week High
$13.00
$42.79

Technical Indicators

Market Signals
Indicator
GGR
TIL
Relative Strength Index (RSI) 48.92 39.37
Support Level $3.73 $10.69
Resistance Level $4.00 $11.42
Average True Range (ATR) 0.14 0.69
MACD -0.04 0.21
Stochastic Oscillator 32.94 21.29

Price Performance

Historical Comparison
GGR
TIL

About GGR Gogoro Inc.

Gogoro Inc is focused on eliminating the barriers to electric fuel adoption to bring swappable electric power within reach of every urban rider. Its battery swapping technology compromises an interoperable platform that seamlessly integrates a comprehensive ecosystem of hardware, software, and services, which consists of Gogoro Smart Batteries, GoStations, Gogoro Network Software & Battery Management Systems, Smartscooter, and related components and kits. Geographical presence in Taiwan and Other countries, majority of its revenue comes from Tiwan.

About TIL Instil Bio Inc.

Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.

Share on Social Networks: